Back to News
Market Impact: 0.4
Connect Biopharma Advances Rademikibart Toward Phase 3 In COPD
Source: Nasdaq
Healthcare & Biotech
Connect Biopharma reported positive topline results from a global Phase 2 trial of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The positive mid-stage clinical data could support further development of the drug candidate and is likely material for CNTB shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- PHC Holdings surge to near 4-year high after Toho takeover proposal confirmed
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI
- How to Track Earnings Call Sentiment Across Companies